Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014 in more than 115 countries, with a direct commercial presence in 30 countries.
Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumors. Ipsen also has a significant presence in primary care.
The Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative technological platforms, peptides and toxins, located in the heart of the leading biotechnological hubs (Les Ulis, Fr ; Slough/Oxford, UK ; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million (about 15% of Group sales).
The Group has more than 4,500 employees.
Company Growth (employees)
Boulogne Billancourt, FR